Swiss researchers develop nanozymes to treat aggressive astrocytomas
A Swiss-led research initiative is developing nanozymes to treat aggressive astrocytomas, targeting a cancer with a five-year survival rate of only 5%. By applying bio-compatible nanomaterials directly during surgery and activating them with near-infrared light, researchers aim to bypass the blood-brain barrier and reduce the 70% recurrence rate. The statistical reality of malignant brain tumors, … Weiterlesen …